Enoxaparin (Clexane®, Lovenox®), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability
Authors:
- A. UzanAUA. Uzan
- P. SedivyPSP. Sedivy
- I. CaveroICI. Cavero
- 1 May 1992
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 66 (2-3) , 191-206
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Enhancement of arterial thrombolysis with native tissue type plasminogen activator by pretreatment with heparin or batroxobin: An angioscopic studyAmerican Heart Journal, 1989
- Tissue Plasminogen ActivatorNew England Journal of Medicine, 1988
- A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip SurgeryNew England Journal of Medicine, 1986
- Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.Circulation, 1986
- Comparative effects of heparin and PK 10169, a low molecular weight fraction, in a canine model of arterial thrombosisThrombosis Research, 1985
- Coronary Thrombolysis with Tissue-Type Plasminogen Activator in Patients with Evolving Myocardial InfarctionNew England Journal of Medicine, 1984
- Clot-Selective Coronary Thrombolysis with Tissue-Type Plasminogen ActivatorScience, 1983
- Influence of heparin;of different heparin fractions and of a low molecular weight heparin-like substance on the mechanism of fibrinolysisThrombosis Research, 1982
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957
- THE NATURE AND ACTION OF THE THROMBOPLASTIC (ZYMOPLASTIC) SUBSTANCE OF THE TISSUESAmerican Journal of Physiology-Legacy Content, 1912